Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.

Takashima Y, Kikuchi E, Kikuchi J, Suzuki M, Kikuchi H, Maeda M, Shoji T, Furuta M, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J, Konno S.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32515. [Epub ahead of print]

PMID:
31199520
2.

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).

Furuta M, Sakakibara-Konishi J, Kikuchi H, Yokouchi H, Nishihara H, Minemura H, Harada M, Yamazaki S, Akie K, Fujita Y, Takamura K, Kojima T, Harada T, Minami Y, Watanabe N, Oizumi S, Suzuki H, Nishimura M, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group.

Oncologist. 2019 May 8. pii: theoncologist.2018-0676. doi: 10.1634/theoncologist.2018-0676. [Epub ahead of print]

PMID:
31068386
3.

Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome.

Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I, Dosaka-Akita H, Iseki K.

Support Care Cancer. 2019 Apr 23. doi: 10.1007/s00520-019-04808-y. [Epub ahead of print]

PMID:
31016422
4.

DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.

Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J.

Cancer Sci. 2019 May;110(5):1599-1608. doi: 10.1111/cas.13997. Epub 2019 Apr 13.

5.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

6.

Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study.

Takeuchi S, Shiga T, Hirata K, Taguchi J, Magota K, Ariga S, Gouda T, Ohhara Y, Homma R, Shimizu Y, Kinoshita I, Tsuji Y, Homma A, Iijima H, Tamaki N, Dosaka-Akita H.

BMJ Open. 2018 Aug 30;8(8):e021001. doi: 10.1136/bmjopen-2017-021001.

7.

Genomic testing for pancreatic cancer in clinical practice as real-world evidence.

Hayashi H, Tanishima S, Fujii K, Mori R, Okamura Y, Yanagita E, Matsuoka R, Amano T, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H.

Pancreatology. 2018 Sep;18(6):647-654. doi: 10.1016/j.pan.2018.07.006. Epub 2018 Jul 25.

PMID:
30055942
8.

Numb has distinct function in lung adenocarcinoma and squamous cell carcinoma.

Kikuchi H, Sakakibara-Konishi J, Furuta M, Kikuchi E, Kikuchi J, Oizumi S, Hida Y, Kaga K, Kinoshita I, Dosaka-Akita H, Nishimura M.

Oncotarget. 2018 Jun 29;9(50):29379-29391. doi: 10.18632/oncotarget.25585. eCollection 2018 Jun 29.

9.

A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).

Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Int J Clin Oncol. 2018 Dec;23(6):1060-1069. doi: 10.1007/s10147-018-1318-z. Epub 2018 Jul 19.

PMID:
30027464
10.

Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Takashima Y, Sakakibara-Konishi J, Hatanaka Y, Hatanaka KC, Ohhara Y, Oizumi S, Hida Y, Kaga K, Kinoshita I, Dosaka-Akita H, Matsuno Y, Nishimura M.

Clin Lung Cancer. 2018 Jul;19(4):352-359.e1. doi: 10.1016/j.cllc.2018.02.004. Epub 2018 Feb 19.

PMID:
29544718
11.

Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials.

Harada T, Amano T, Ikari T, Takamura K, Ogi T, Fujikane T, Fujita Y, Taima K, Tanaka H, Sasaki T, Okumura S, Sugawara S, Yokouchi H, Yamada N, Morikawa N, Dosaka-Akita H, Isobe H, Nishimura M.

Front Pharmacol. 2018 Jan 16;8:972. doi: 10.3389/fphar.2017.00972. eCollection 2017.

12.

Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors.

Hontani K, Tsuchikawa T, Hiwasa T, Nakamura T, Ueno T, Kushibiki T, Takahashi M, Inoko K, Takano H, Takeuchi S, Dosaka-Akita H, Kuwatani M, Sakamoto N, Hatanaka Y, Mitsuhashi T, Shimada H, Shichinohe T, Hirano S.

Oncotarget. 2017 Oct 31;8(63):106206-106221. doi: 10.18632/oncotarget.22175. eCollection 2017 Dec 5.

13.

A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).

Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Cancer Chemother Pharmacol. 2017 Nov;80(5):955-963. doi: 10.1007/s00280-017-3432-4. Epub 2017 Sep 13.

14.

Autophagy-dependent regulation of tumor metastasis by myeloid cells.

Jinushi M, Morita T, Xu Z, Kinoshita I, Dosaka-Akita H, Yagita H, Kawakami Y.

PLoS One. 2017 Jul 7;12(7):e0179357. doi: 10.1371/journal.pone.0179357. eCollection 2017.

15.

Expression of Notch1 and Numb in small cell lung cancer.

Kikuchi H, Sakakibara-Konishi J, Furuta M, Yokouchi H, Nishihara H, Yamazaki S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Harada T, Higuchi M, Honjo O, Minami Y, Watanabe N, Oizumi S, Suzuki H, Ishida T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M.

Oncotarget. 2017 Feb 7;8(6):10348-10358. doi: 10.18632/oncotarget.14411.

16.

Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker.

Yokouchi H, Nishihara H, Harada T, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Goto A, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M.

Oncotarget. 2017 Jun 13;8(24):39711-39726. doi: 10.18632/oncotarget.14410.

17.

Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology.

Hirayama Y, Sasaki J, Dosaka-Akita H, Ishitani K.

ESMO Open. 2016 May 13;1(3):e000053. eCollection 2016.

18.

Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.

Sakakibara-Konishi J, Ikezawa Y, Oizumi S, Kikuchi J, Kikuchi E, Mizugaki H, Kinoshita I, Dosaka-Akita H, Nishimura M.

Int J Clin Oncol. 2017 Apr;22(2):257-268. doi: 10.1007/s10147-016-1060-3. Epub 2016 Nov 5.

PMID:
27816990
19.

Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.

Saito Y, Kobayashi M, Yamada T, Kasashi K, Honma R, Takeuchi S, Shimizu Y, Kinoshita I, Dosaka-Akita H, Iseki K.

Support Care Cancer. 2017 Feb;25(2):481-487. doi: 10.1007/s00520-016-3426-5. Epub 2016 Oct 3.

PMID:
27699503
20.

Role of targeted therapy in metastatic colorectal cancer.

Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H.

World J Gastrointest Oncol. 2016 Sep 15;8(9):642-55. doi: 10.4251/wjgo.v8.i9.642. Review.

21.

Lobe-Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi-Institutional Retrospective Study Using a Propensity Score Analysis.

Hishida T, Miyaoka E, Yokoi K, Tsuboi M, Asamura H, Kiura K, Takahashi K, Dosaka-Akita H, Kobayashi H, Date H, Tada H, Okumura M, Yoshino I; Japanese Joint Committee of Lung Cancer Registry.

J Thorac Oncol. 2016 Sep;11(9):1529-37. doi: 10.1016/j.jtho.2016.05.014. Epub 2016 May 29.

22.

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.

Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M, Dosaka-Akita H.

Cancer Sci. 2016 Jul;107(7):955-62. doi: 10.1111/cas.12957. Epub 2016 Jun 13.

23.

Novel signaling collaboration between TGF-β and adaptor protein Crk facilitates EMT in human lung cancer.

Elmansuri AZ, Tanino MA, Mahabir R, Wang L, Kimura T, Nishihara H, Kinoshita I, Dosaka-Akita H, Tsuda M, Tanaka S.

Oncotarget. 2016 May 10;7(19):27094-107. doi: 10.18632/oncotarget.8314.

24.

Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A).

Yokouchi H, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Fukuhara T, Takamura K, Kojima T, Harada T, Higuchi M, Matsuura Y, Honjo O, Minami Y, Watanabe N, Nishihara H, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M.

Lung Cancer. 2015 Dec;90(3):548-53. doi: 10.1016/j.lungcan.2015.10.010. Epub 2015 Oct 14.

PMID:
26604032
25.

Surgical Intervention for Non-Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004.

Iida T, Shiba M, Yoshino I, Miyaoka E, Asamura H, Date H, Okumura M, Tada H, Nakanishi Y, Dosaka-Akita H, Kobayashi H, Takahashi K, Inoue M, Yokoi K; Japanese Joint Committee of Lung Cancer Registry.

J Thorac Oncol. 2015 Jul;10(7):1076-82. doi: 10.1097/JTO.0000000000000554.

26.

Decreased proteasomal function accelerates cigarette smoke-induced pulmonary emphysema in mice.

Yamada Y, Tomaru U, Ishizu A, Ito T, Kiuchi T, Ono A, Miyajima S, Nagai K, Higashi T, Matsuno Y, Dosaka-Akita H, Nishimura M, Miwa S, Kasahara M.

Lab Invest. 2015 Jun;95(6):625-34. doi: 10.1038/labinvest.2015.43. Epub 2015 Apr 27.

27.

The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas.

Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K, Yamada S, Nakayama T, Kitada S, Suzu S, Kinoshita I, Dosaka-Akita H, Akashi K, Takeya M, Jinushi M.

Cancer Immunol Res. 2015 Sep;3(9):999-1007. doi: 10.1158/2326-6066.CIR-14-0156. Epub 2015 Mar 17.

28.

Expression of fucosyltransferase 8 is associated with an unfavorable clinical outcome in non-small cell lung cancers.

Honma R, Kinoshita I, Miyoshi E, Tomaru U, Matsuno Y, Shimizu Y, Takeuchi S, Kobayashi Y, Kaga K, Taniguchi N, Dosaka-Akita H.

Oncology. 2015;88(5):298-308. doi: 10.1159/000369495. Epub 2015 Jan 7.

PMID:
25572677
29.

Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.

Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, Harada T, Harada M, Takamura K, Oizumi S, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1149-57. doi: 10.1007/s00280-014-2589-3. Epub 2014 Oct 8.

PMID:
25294632
30.

Surgery for small cell lung cancer: a retrospective analysis of 243 patients from Japanese Lung Cancer Registry in 2004.

Takei H, Kondo H, Miyaoka E, Asamura H, Yoshino I, Date H, Okumura M, Tada H, Fujii Y, Nakanishi Y, Eguchi K, Dosaka-Akita H, Kobayashi H, Sawabata N, Yokoi K; Japanese Joint Committee of Lung Cancer Registry.

J Thorac Oncol. 2014 Aug;9(8):1140-5. doi: 10.1097/JTO.0000000000000226.

31.

Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4.

Jinushi T, Shibayama Y, Kinoshita I, Oizumi S, Jinushi M, Aota T, Takahashi T, Horita S, Dosaka-Akita H, Iseki K.

Cancer Med. 2014 Dec;3(6):1544-52. doi: 10.1002/cam4.309. Epub 2014 Aug 1.

32.

Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.

Yokouchi H, Kanazawa K, Ishida T, Oizumi S, Shinagawa N, Sukoh N, Harada M, Ogura S, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M.

Mol Clin Oncol. 2014 Sep;2(5):744-750. Epub 2014 Jun 19.

33.

Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells.

Yamashina T, Baghdadi M, Yoneda A, Kinoshita I, Suzu S, Dosaka-Akita H, Jinushi M.

Cancer Res. 2014 May 15;74(10):2698-709. doi: 10.1158/0008-5472.CAN-13-2169. Epub 2014 Mar 17.

34.

HPV-associated lung cancers: an international pooled analysis.

Ragin C, Obikoya-Malomo M, Kim S, Chen Z, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, Carpagnano GE, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, Gorgoulis V, Heideman DA, van Boerdonk RA, Hiroshima K, Iwakawa R, Kastrinakis NG, Kinoshita I, Akiba S, Landi MT, Eugene Liu H, Wang JL, Mehra R, Khuri FR, Lim WT, Owonikoko TK, Ramalingam S, Sarchianaki E, Syrjanen K, Tsao MS, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E.

Carcinogenesis. 2014 Jun;35(6):1267-75. doi: 10.1093/carcin/bgu038. Epub 2014 Feb 12.

35.

TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance.

Baghdadi M, Yoneda A, Yamashina T, Nagao H, Komohara Y, Nagai S, Akiba H, Foretz M, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Takeya M, Viollet B, Yagita H, Jinushi M.

Immunity. 2013 Dec 12;39(6):1070-81. doi: 10.1016/j.immuni.2013.09.014. Epub 2013 Dec 5.

36.

Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.

Zhao S, Kuge Y, Zhao Y, Takeuchi S, Hirata K, Takei T, Shiga T, Dosaka-Akita H, Tamaki N.

BMC Cancer. 2013 Nov 6;13:525. doi: 10.1186/1471-2407-13-525.

37.

CD133 expression: a potential prognostic marker for non-small cell lung cancers.

Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E, Kinoshita I, Oizumi S, Dosaka-Akita H, Matsuno Y, Nishimura M.

Int J Clin Oncol. 2014 Apr;19(2):254-9. doi: 10.1007/s10147-013-0541-x. Epub 2013 Mar 12.

PMID:
23479121
38.

A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.

Harada T, Oizumi S, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, Inoue A, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Oncologist. 2013;18(4):439-45. doi: 10.1634/theoncologist.2012-0308. Epub 2013 Feb 26.

39.

Method for the validation of immunohistochemical staining using SCID mouse xenografts: expression of CD40 and CD154 in human non-small cell lung cancer.

Ishikawa K, Miyamoto M, Yoshioka T, Kadoya M, Li L, Mishra R, Ichinokawa K, Shoji Y, Matsumura Y, Hida Y, Kaga K, Kato T, Kaji M, Ohbuchi T, Itoh T, Dosaka-Akita H, Matsui Y, Hirano S.

Oncol Rep. 2013 Apr;29(4):1315-21. doi: 10.3892/or.2013.2275. Epub 2013 Feb 5.

40.

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas.

Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M.

Cancer Immunol Immunother. 2013 Apr;62(4):629-37. doi: 10.1007/s00262-012-1371-9. Epub 2012 Nov 10.

PMID:
23143694
41.

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H.

Lung Cancer. 2012 Nov;78(2):138-43. doi: 10.1016/j.lungcan.2012.08.003. Epub 2012 Aug 25.

42.

Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.

Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M.

Nat Immunol. 2012 Sep;13(9):832-42. doi: 10.1038/ni.2376. Epub 2012 Jul 29.

43.

Expression of Bim, Noxa, and Puma in non-small cell lung cancer.

Sakakibara-Konishi J, Oizumi S, Kikuchi J, Kikuchi E, Mizugaki H, Kinoshita I, Dosaka-Akita H, Nishimura M.

BMC Cancer. 2012 Jul 12;12:286. doi: 10.1186/1471-2407-12-286.

44.

Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients.

Tanaka K, Tsuchikawa T, Miyamoto M, Maki T, Ichinokawa M, Kubota KC, Shichinohe T, Hirano S, Ferrone S, Dosaka-Akita H, Matsuno Y, Kondo S.

Int J Oncol. 2012 Apr;40(4):965-74. doi: 10.3892/ijo.2011.1274. Epub 2011 Nov 30.

45.

ATM-mediated DNA damage signals mediate immune escape through integrin-αvβ3-dependent mechanisms.

Jinushi M, Chiba S, Baghdadi M, Kinoshita I, Dosaka-Akita H, Ito K, Yoshiyama H, Yagita H, Uede T, Takaoka A.

Cancer Res. 2012 Jan 1;72(1):56-65. doi: 10.1158/0008-5472.CAN-11-2028. Epub 2011 Nov 17.

46.

Phase II study of irinotecan plus S-1 combination for previously untreated advanced non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601.

Akie K, Oizumi S, Ogura S, Shinagawa N, Kikuchi E, Fukumoto S, Harada M, Kinoshita I, Kojima T, Harada T, Fujita Y, Ohsaki Y, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Oncology. 2011;81(2):84-90. doi: 10.1159/000331681. Epub 2011 Oct 3.

PMID:
21968255
47.

Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells.

Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H.

Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30. doi: 10.1073/pnas.1106645108. Epub 2011 Jul 11.

48.

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy.

Takeuchi S, Honma R, Taguchi J, Amano T, Shimizu Y, Kinoshita I, Kubota K, Matsuno Y, Dosaka-Akita H.

Case Rep Oncol. 2011 May;4(2):260-6. doi: 10.1159/000328802. Epub 2011 May 24.

49.

18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.

Takeuchi S, Zhao S, Kuge Y, Zhao Y, Nishijima K, Hatano T, Shimizu Y, Kinoshita I, Tamaki N, Dosaka-Akita H.

Oncol Rep. 2011 Sep;26(3):725-30. doi: 10.3892/or.2011.1338. Epub 2011 Jun 7.

PMID:
21667030
50.

Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.

Asahina H, Oizumi S, Inoue A, Kinoshita I, Ishida T, Fujita Y, Sukoh N, Harada M, Maemondo M, Saijo Y, Dosaka-Akita H, Isobe H, Nukiwa T, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Oncology. 2010;79(5-6):423-9. doi: 10.1159/000326488. Epub 2011 Apr 8.

Supplemental Content

Loading ...
Support Center